AlphaStocks

AMPH vs LLY

As of Sep 20, 2026, Amphastar Pharmaceuticals (AMPH) scores 7.5/10 and ELI LILLY (LLY) 7.2/10 on AlphaStocks' five-model composite, so AMPH scores higher. LLY trades 76% above its model fair value.

AMPH

Amphastar Pharmaceuticals, Inc.

7.5

Strong Buy

$23.60

LLY

ELI LILLY & Co

7.2

Consider Buy

$1,152.46

AMPH vs LLY: Which is the Better Investment?

Amphastar Pharmaceuticals, Inc. (AMPH) scores 7.5/10 while ELI LILLY & Co (LLY) scores 7.2/10 on AlphaStocks' composite model. Amphastar Pharmaceuticals, Inc. has the higher composite rating of Strong Buy.

This comparison is algorithmically generated and is not financial advice.

MetricAMPHLLY
Scores & Fundamentals
Composite Score7.5/107.2/10
RatingStrong BuyConsider Buy
Price$23.60$1,152.46
P/E Ratio50.2
ROE82.0%
Market Cap$1B$1.0T
Fair Value$656.48
Dividend Yield0.5%
Sector Rank#4 of 168#11 of 168
Model Verdicts
PiotroskiAttractiveStrong
BuffettAttractiveStrong
GrahamAttractiveCaution
LynchAttractiveNeutral
GreenblattAttractiveCaution
View full AMPHanalysis →View full LLYanalysis →

Related comparisons

Compare any two stocks →

AMPH vs LLY: Which Stock Scores Higher?

Amphastar Pharmaceuticals, Inc. (AMPH) and ELI LILLY & Co (LLY) are both in the Health Care sector. AMPH currently leads with a composite score of 7.5/10 (Strong Buy) compared to LLY's 7.2/10 (Consider Buy).

The AlphaStocks composite score evaluates each stock across four dimensions: Quality (business strength measured by Piotroski F-Score and Buffett quality criteria), Value (discount to intrinsic worth using Graham, Lynch, and Greenblatt models), Momentum (6-month price trend), and Timing (a confirmation signal that requires both value and momentum to align). A higher composite score indicates stronger overall fundamentals combined with favorable market conditions.

This comparison uses the same scoring framework for both companies, ensuring an apples-to-apples evaluation. Scores are recalculated daily after market close using data from SEC filings and market prices. Read the full methodology to understand how each model contributes to the composite score.

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer